Supplier News

Oct 23, 2017
By BioPharm International Editors
The clinical-stage biopharmaceutical company has announced the opening of a new gene therapy manufacturing facility in Modiin, Israel, which is anticipated to be the production site of the company’s lead cancer drug candidate.
Oct 20, 2017
By BioPharm International Editors
The companies will embark on a joint antimicrobial research project, with the intent to discover antibiotic combinations that target resistance.
Oct 20, 2017
By BioPharm International Editors
The company has announced that it has acquired a new bioanalysis and biomarkers services facility in Laval, Montreal, Canada to support preclinical and clinical programs.
Oct 20, 2017
By BioPharm International Editors
SCHOTT began production of glass ampoules, vials, and cartridges at a new facility at the SCHOTT Xinkang headquarters in Zhejiang, China.
Oct 19, 2017
By BioPharm International Editors
The two companies announced their collaboration for the production and development of cancer vaccines.
Oct 17, 2017
By BioPharm International Editors
DSM Sinochem Pharmaceuticals has filed a lawsuit against CSPC Pharmaceutical Group, Inner Mongolia Changsheng Pharmaceutical Company, and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) for infringement of its amoxicillin patent.
Oct 17, 2017
By BioPharm International Editors
Almac Group’s Almac Pod, a temperature-controlled shipping solution service for biologics and other temperature-sensitive products, is available in the United States.
Oct 16, 2017
By BioPharm International Editors
The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.
Oct 16, 2017
By BioPharm International Editors
The Belgian biopharmaceutical company has formed a subsidiary in the United States, and appointed Daniel Schneider as its general manager.
Oct 16, 2017
By BioPharm International Editors
Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology.
native1_300x100
lorem ipsum